TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9553290
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin (0.2 mg/kg per dose every 12 to 24 hours for three doses)
Study: 2262233
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin
Study: 8067791
Drug: Prednisolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (2 mg/kg daily for 14 days, then 1 mg/kg on alternate days for 10 weeks)
Study: 22929636
Drug: Clonidine 150
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 150 mcg
Study: 30738795
Drug: Vascular endothelial
Normalized name: Vascular endothelial growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular endothelial growth factor-targeted therapy
Study: 21813917
Drug: Q-chews (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-chews (4 chews providing 1,000 mg quercetin, 120 mg epigallocatechin 3-gallate, 400 mg isoquercetin, 400 mg each eicosapentaenoic acid and docosahexaenoic acid, 1,000 mg vitamin C, and 40 mg niacinamide)
Study: 10928305
Drug: ipsapirone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone (20 mg orally)
Study: 8342392
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (GH), 0.25 IU/kg/week for 6 months (0.125 IU/kg/week during the first month)
Study: 19690310
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg oral estradiol (daily)
Study: 16296255
Drug: 0.45% stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% stannous fluoride gel
Study: 27113945
Drug: Periarticular liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular liposomal bupivacaine injection
Study: 27113945
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection of bupivacaine/morphine
Study: 27113945
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of bupivacaine/morphine
Study: 22416789
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (oral and written information)
Study: 18534051
Drug: MAP0004 (orally-inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP0004 (orally-inhaled DHE)
Study: 12803268
Drug: Oral fentanyl
Normalized name: fentanyl Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fentanyl (0.1 mg)
Study: 12803268
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (5 mg)
Study: 1893319
Drug: Standard DPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DPT vaccine
Study: 1893319
Drug: Modified DPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified DPT vaccine
Study: 6678824
Drug: Dilazep, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilazep, 300 mg daily
Study: 6678824
Drug: Acetylsalicylic acid,
Normalized name: Acetylsalicylic Acid, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylic acid, 100 mg daily or dipyridamole, 300 mg daily
Study: 30975379
Drug: high DHA
Normalized name: Fish Oil/Stevia Extract 850 MG-10 MG Oral Packet [COROMEGA CHILD BRAIN & BODY HIGH DHA OMEGA-3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: high DHA multi-nutrient supplement and exercise
Study: 30975379
Drug: placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo supplement and exercise
Study: 30975379
Drug: high DHA
Normalized name: Fish Oil/Stevia Extract 850 MG-10 MG Oral Packet [COROMEGA CHILD BRAIN & BODY HIGH DHA OMEGA-3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: high DHA multi-nutrient supplement
Study: 30975379
Drug: placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo supplement
Study: 27935924
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of nicotine replacement therapies
Study: 18259090
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin
Study: 16181824
Drug: Milrinone, dobutamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone, dobutamine, nitroglycerin, nitroprusside, nesiritide (established drugs approved by the FDA)
Study: 22658895
Drug: Molar insulin-to-C-peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molar insulin-to-C-peptide ratio (I/C) > 0.175
Study: 22658895
Drug: Metformin and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and/or thiazolidinedione usage
Study: 19407666
Drug: Placebo (placebo/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo/placebo and placebo/L-methionine)
Study: 18085911
Drug: Community residential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community residential treatment (n=139)
Study: 18085911
Drug: Treatment beyond
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment beyond the index stay
Study: 11781675
Drug: Sterol esters
Normalized name: lanosterol esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterol esters (2.4 g)
Study: 11781675
Drug: Stanols (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanols (2.4 g)
Study: 9476087
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.05 mg/day) and norethisterone acetate orally (2.5 mg/day) for 12 days every 2 months (group A)
Study: 9476087
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.05 mg/day) and norethisterone acetate orally (2.5 mg/day) for 12 days every 3 months (group B)
Study: 24919385
Drug: Meclizine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclizine (25 mg)
Study: 24346808
Drug: Promethazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (25 mg) plus D-Amphetamine (10 mg)
Study: 7004560
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent chlorambucil
Study: 7004560
Drug: Five-drug combination
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug combination (chlorambucil, methotrexate, fluorouracil, vincristine, adriamycin)
Study: 30730274
Drug: Birch pollen
Normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch pollen allergoid subcutaneous immunotherapy (4 weekly injections)
Study: 30730274
Drug: Birch pollen
Normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch pollen allergoid subcutaneous immunotherapy (7 weekly injections)
Study: 28671856
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg intravenously every 2 weeks
Study: 28073844
Drug: Dacarbazine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine 1,000 mg/m2 intravenously every 3 weeks
Study: 26060154
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (20 minutes, twice a day for four days)
Study: 17551378
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment consisting of scaling/root planing and oral hygiene instruction
Study: 17142410
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.5% bupivacaine into the iliac crest harvest site
Study: 17142410
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received morphine sulfate via patient-controlled analgesia pump
Study: 14512038
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements (352 kcal/day)
Study: 10658936
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (8 mg/kg)
Study: 10658936
Drug: N(G)-monomethyl-L-arginine (L-NMMA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-monomethyl-L-arginine (L-NMMA; 3 mg/kg) after CsA
Study: 21270268
Drug: N(G)-monomethyl-L-arginine (L-NMMA)
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-monomethyl-L-arginine (L-NMMA)
Study: 7551612
Drug: Daily live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily live self-exposure and ritual prevention to external cues (Ex)
Study: 7551612
Drug: Daily self-exposure
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-exposure to imagined internal cues of the consequences of not ritualising (Exi)
Study: 8873695
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nicardipine
Study: 3004113
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg captopril
Study: 31619393
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control therapy
Study: 31619393
Drug: Active TWO2
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TWO2 therapy (after adjustment for UTC grade)
Study: 19632949
Drug: S-1 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (oral fluoropyrimidine)
Study: 18060441
Drug: ramelteon 16
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ramelteon 16 mg
Study: 10587552
Drug: Calcitriol -
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol - 0.5 microg daily
Study: 28067086
Drug: Prophylactic dose
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dose of 600 mg of clindamycin, continued with clindamycin postoperatively
Study: 28067086
Drug: Prophylactic chlorhexidin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic chlorhexidin rinsing, continued randomized amoxicillin clavulanate or clindamycin postoperatively
Study: 25725179
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose methylprednisolone infusion (1mg/kg loading dose followed by 2mg/Kg/24 hours for 1 day)
Study: 15142155
Drug: lidocaine‐prilocaine solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine‐prilocaine solution
Study: 15142155
Drug: inert cream
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: inert cream
Study: 11300448
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral estradiol for three months
Study: 24158593
Drug: Fosdevirine 200
Normalized name: Fosdevirine
DrugBank: Fosdevirine (DB06166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosdevirine 200 mg
Study: 24158593
Drug: Control (Etravirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Etravirine 200 mg twice daily)
Study: 14700098
Drug: BSS with
Normalized name: BSS Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSS with antibiotics (vancomycin and gentamycin)
Study: 11053334
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg/kg)
Study: 1555950
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam irradiation to a dose of 2000 cGy delivered in 10 fractions over 2 weeks (Group A)
Study: 1555950
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate intracavitary irradiation to a dose of 1200 cGy delivered in two sessions of 600 cGy each a week apart (Group B)
Study: 21863028
Drug: Focal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal therapy
Study: 10458683
Drug: Radical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical treatment
Study: 16724990
Drug: HAI alternating
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI alternating with systemic chemotherapy (HA + SC group)
Study: 9559492
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) (50.0 mg/ml for 5 minutes)
Study: 9559492
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mitomycin C (MMC) (0.5 mg/ml for 3.5 minutes)
Study: 7871085
Drug: Scopolamine (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.3, 0.6 mg IM)
Study: 17283283
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg oral)
Study: 7871085
Drug: Scopolamine and
Normalized name: butylscopolamine and analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine and Lorazepam (active treatments)
Study: 3281516
Drug: Naftidrofuryl (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (400 mg, two times daily for eight weeks)
Study: 3281516
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two identical tablets daily for eight weeks)
Study: 1138025
Drug: DL-methionine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-methionine supplementation at 0.58 g/day
Study: 11211063
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg)
Study: 23694974
Drug: NeuroBloc® at
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroBloc® at 50 U/ml
Study: 23694974
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of mean anhidrotic area per unit for 100 U/ml of each product
Study: 22151935
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied creatine-containing face-care formulation for 6 weeks
Study: 19192466
Drug: Mirtazapine 30
Normalized name: mirtazapine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 30 mg at bedtime for 30 days
Study: 11211743
Drug: Low concentration/high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration/high volume group (LC/HV, 240 ml of total volume and 5 ml.h‐1 of infusion rate, n = 20)
Study: 11211743
Drug: High concentration/low
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration/low volume group (HC/LV, 96 ml of total volume and 2 ml.h‐1 of infusion rate, n = 20)
Study: 25332252
Drug: Clinical Treatment
Normalized name: Clinicalm
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clinical Treatment Score (CTS)
Study: 21118565
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml of green tea
Study: 12568411
Drug: No Hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Hormone Replacement Therapy (no HRT)
Study: 11748515
Drug: Sufentanil administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil administered by target‐controlled infusion (target effect‐site concentrations ranging from 0.4 to 4.5 ng/mL)
Study: 11748515
Drug: Concomitant medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant medications (lorazepam, morphine‐scopolamine, clonidine, or propofol)
Study: 25370890
Drug: Nutri-jelly (200-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutri-jelly (200-ml box as daily supplement throughout radiotherapy)
Study: 15498086
Drug: Repaglinide dose
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide dose titration based on post-prandial glucose levels
Study: 15498086
Drug: Repaglinide dose
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide dose titration based on pre-prandial glucose levels
Study: 15498086
Drug: Repaglinide dose
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide dose titration based on post-prandial glucose levels in metformin-treated individuals
Study: 15498086
Drug: Repaglinide dose
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide dose titration based on pre-prandial glucose levels in metformin-treated individuals
Study: 15498086
Drug: Repaglinide dose
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide dose titration
Study: 8586785
Drug: Chlorine covers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorine covers generated by bathing hands in a solution of 2% sodium tosylchloramide for 1 min.
Study: 8586785
Drug: Dechlorinated hands
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dechlorinated hands (bathing in a solution of 0.5% sodium thiosulphate for 15 s).
Study: 767390
Drug: Active alert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active alert hypnotic induction (riding a bicycle ergometer under load, keeping eyes open, receiving suggestions of alertness)
Study: 767390
Drug: Traditional relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional relaxation induction (standard eye fixation and relaxation induction of the Stanford Hypnotic Susceptibility Scale, Form B)
Study: 11146708
Drug: No antipyretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antipyretic treatment (Control)
Study: 1827106
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg 12-hourly
Study: 1827106
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg 8-hourly
Study: 7015934
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens (aminophylline + subcutaneously administered epinephrine or inhaled isoproterenol)
Study: 31084563
Drug: Photobiomodulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation treatment (RTG)
Study: 31084563
Drug: Photobiomodulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation treatment (LTG)
Study: 28679189
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dapoxetine two hours before sexual relations for 3 months (Group A)
Study: 28679189
Drug: Dynamic rehabilitative
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic rehabilitative treatment (Group B)
Study: 28679189
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment in association with dynamic rehabilitative behavioural treatment for 3 months (Group C)
Study: 26505826
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (0.8‐g/kg protein, 70% animal and 30% plant proteins)
Study: 20920295
Drug: Prolastin-C (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin-C (60 mg/kg by weekly intravenous infusion for 8 weeks)
Study: 20920295
Drug: Prolastin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin (60 mg/kg by weekly intravenous infusion for 8 weeks)
Study: 20920295
Drug: Prolastin-C (double-blind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin-C (double-blind treatment phase only)
Study: 10325828
Drug: Alveolar recruitment
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alveolar recruitment strategy with PEEP 15 cm H2O and tidal volume of 18 ml kg‐1 or peak inspiratory pressure of 40 cm H2O
Study: 4076329
Drug: Lignocaine 250
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 250 mg orally
Study: 4076329
Drug: Lignocaine 50
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 50 mg intravenously
Study: 29577973
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (200 mg)
Study: 26446328
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg solifenacin per day
Study: 26446328
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg fesoterodine per day
Study: 20001977
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion of short acting insulin
Study: 11834235
Drug: MPA+E(2)C injection
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA+E(2)C injection on Day 5 of the menstrual cycle (control group, n = 41)
Study: 30275886
Drug: Fenofibrate treatment
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate treatment
Study: 30021076
Drug: Parenteral epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral epinephrine
Study: 27064136
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol 3 g orally on days 1, 3, and 5
Study: 27064136
Drug: Ceftriaxone 250
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 250 mg intramuscularly plus azithromycin 1 g orally as a single dose
Study: 25403144
Drug: Mentalization-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-Based Treatment in a day hospitalization setting (MBT-DH)
Study: 25403144
Drug: Mentalization-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-Based Treatment in an intensive outpatient setting (MBT-IOP)
Study: 21769873
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (100 mg kg(‐1))